Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Malkhasyan

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Endocrine Reviews|June 5, 2024
Teprotumumab for the Treatment of Thyroid Eye DiseaseShoaib Ugradar, Emil Malkhasyan, Raymond S Douglas
Thyroid : Official Journal of the American Thyroid Association|November 14, 2023
A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye DiseaseRaymond S Douglas, Emanuil Parunakian, Joseph Tolentino, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 19, 2024
Teprotumumab improves light sensitivity in patients with thyroid eye diseaseEmanuil Parunakian, Shoaib Ugradar, Joseph Tolentino, et al.
Ophthalmic Plastic and Reconstructive Surgery|December 23, 2024
Clinical and Radiologic Predictors of Response to Teprotumumab: A 3D Volumetric Analysis of 35 PatientsShoaib Ugradar, Emanuil Parunakian, Erin Zimmerman, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 13, 2024
Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case seriesShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Ophthalmology|January 17, 2025
ReplyShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Ophthalmology|July 20, 2024
The Rate of Re-treatment in Patients Treated with Teprotumumab: A Multicenter Study of 119 Patients with 1 Year of Follow-upShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Endocrine Reviews|June 5, 2024
Teprotumumab for the Treatment of Thyroid Eye DiseaseShoaib Ugradar, Emil Malkhasyan, Raymond S Douglas
Thyroid : Official Journal of the American Thyroid Association|November 14, 2023
A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye DiseaseRaymond S Douglas, Emanuil Parunakian, Joseph Tolentino, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 19, 2024
Teprotumumab improves light sensitivity in patients with thyroid eye diseaseEmanuil Parunakian, Shoaib Ugradar, Joseph Tolentino, et al.
Ophthalmic Plastic and Reconstructive Surgery|December 23, 2024
Clinical and Radiologic Predictors of Response to Teprotumumab: A 3D Volumetric Analysis of 35 PatientsShoaib Ugradar, Emanuil Parunakian, Erin Zimmerman, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 13, 2024
Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case seriesShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Ophthalmology|January 17, 2025
ReplyShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Ophthalmology|July 20, 2024
The Rate of Re-treatment in Patients Treated with Teprotumumab: A Multicenter Study of 119 Patients with 1 Year of Follow-upShoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, et al.
Pageof 1